# The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer

> **NCT03985891** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 40 (estimated)

## Conditions studied

- Colonic Neoplasms
- Chemotherapy Effect

## Interventions

- **DRUG:** Anti-PD-1 Monoclonal Antibody JS001
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03985891
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-16
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985891, "The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03985891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*